About Us

FibroGenesis is undertaking an accelerated preclinical program to find a cure for COVID-19 Acute Respiratory Distress Syndrome (ARDS) using its advanced fibroblast cell therapy.

Multi-Pronged Attack on COVID-19:

FibroMune™ and PneumoBlast™

We are developing two products for treatment of COVID-19.  The first, FibroMune™, is comprised of conditioned media from activated fibroblasts, which induces interferon beta production when administered.  FibroMune™ is being developed to activate innate immunity in order to prevent virus propagation.  PneumoBlast™ is comprised of proprietary “universal donor” fibroblasts for the treatment of acute respiratory distress syndrome (ARDS), which is the main cause of COVID-19 mortality.  PneumoBlast™ reduces pulmonary pathology in mouse models of ARDS as well as protects/regenerates type II pulmonary epithelial cells.  We are seeking to conduct experiments in animal models of SARS-Cov-2 and toxicity evaluation to support FDA Investigational New Drug (IND) filing to enable clinical trials.


FibroGenesis, is a regenerative medicine company developing an innovative regenerative medicine solution for chronic diseases using fibroblasts. Currently, FibroGenesis holds 235 U.S. and international issued patents issued/pending across a variety of clinical pathways, including Disc Degeneration, Multiple Sclerosis, Parkinson’s, Chronic Traumatic Encephalopathy, Colitis, Cancer, Diabetes, Liver Failure and Heart Failure. FibroGenesis represents the next generation of medical advancement in cell therapy.

Pete O’Heeron, MSHA, CEO FibroGenesis, LLC

Mr. O’Heeron serves as our Chief Executive Officer. As a seasoned leader he has over 20 years of medical technology and biotech development experience. Mr O’Heeron brings together the resources necessary to commercialize unique technologies. His expertise covers a broad range of disciplines, from business start-ups and biologics, to medical devices and patient centered healthcare delivery.  Mr. O'Heeron holds 150+ Patents Issued/Pending.  Together with Dr. Ichim, Mr. O'Heeron holds more Patents Issued/Pending on fibroblasts than the rest of the world combined.

Prior to founding FibroGenesis (formerly named SpinalCyte), LLC, Mr. O’Heeron founded and still serves as CEO of an operational investment group, Advanced Medical Technologies, LLC, which identifies early stage opportunities in the medical field with strong intellectual property potential. Mr. O’Heeron's previous experience includes the founding of NeoSurg Technologies to develop a minimally invasive access system. As a result of his efforts, NeoSurg Technologies was successful in launching the T2000 Minimally Invasive Access System and Mr. O’Heeron completed the sale of NeoSurg Technologies to CooperSurgical.  Mr. O’Heeron was employed by Christus Health Care Corporation in a variety of executive-level positions.  Mr. O’Heeron has provided strategic advisory services to healthcare companies in the areas of biologics, surgical instrumentation and telemedicine.

Mr. O’Heeron received his Masters in Healthcare Administration from the University of Houston.  Mr. O’Heeron completed Executive Management Certification in Mergers and Acquisition from University of Chicago and holds a Bachelor’s Degree in Healthcare Administration with a minor in Business Administration from Texas State University.

Mr. O’Heeron holds the following 14 Patents, with 63 Patents currently pending.

  • Patent 2014317861  Australia "Gene Therapy for the Regeneration of Chondrocytes or Cartilage Type Cells"

  • Patent 10,206,954 Adipose Cells For Chondrocyte Applications

  • Patent 6456826 Japan “Generation Of Cartilage Ex Vivo From Fibroblasts”

  • Patent 2013299505  Australia  “Generation Of Cartilage Ex Vivo From Fibroblasts”

  • Patent 6,280,417 “Trocar”

  • Patent 6,340,358 “Trocar”

  • Patent 6,544,277 “Obturator Assembly”

  • Patent 6,783,516 “Trocar”

  • Patent 6,830,578 “Trocar”

  • Patent 6,835,201 “Trocar”

  • Patent 6,960,164 “Obturator Tip for Trocar”

  • Patent 7,320,694 “Obturator Tip”

  • Patent EP1453426B1 Trocar With Improved Piercing Tip

  • Patent DE60232360D1 Trokar With Improved One Durchstechdorn

Thomas Ichim, Ph.D, Chief Scientific Officer

Thomas Ichim, Ph.D, Chief Scientific Officer, has more than 20 years of broad biotechnology experience including filing and prosecuting patents (over 100 patents filed and issued), publishing in peer reviewed journals (110 publications) obtaining regulatory approvals, conducting clinical trials, and successfully providing return to investors by taking companies public or selling of companies. Dr. Ichim is the world's foremost expert on the therapeutic activities on fibroblasts.  He was cofounder of bioRASI, a fully integrated CRO which made the INC 500 list for fastest growing companies in the USA.  He subsequently joined Medistem Inc, a stem cell company which was purchased by the NYSE traded company Intrexon. Dr. Ichim was co-founder of Batu Biologics, a cancer vaccine, Regen BioPharma, and Creative Medical Technology Holdings, both of which he successfully took public. Dr. Ichim is peer-reviewed for multiple scientific journals and sits on the Editorial Board of the Journal of Translational Medicine.  Dr. Ichim is author/coauthor of multiple book chapters and 3 textbooks.

Top Patents:

  • Patent 8,241,621 Stem cell mediated treg activation/expansion for therapeutic immune modulation. Covers immune regulatory cells in adipose tissues and was sold to public company Cytori Inc.


  • Patent 8,288,172 Extracorporeal removal of microvesicular particles. Covers ways of treating cancer by removing cancer-produced immune poisons called “exosomes”.  This was sold to pubic company Aethlon Medical.


  • Patent 8,372,797 Treatment of erectile dysfunction by stem cell therapy. Covers use of stem cells for treatment of erectile dysfunction in patients in which pharmacological approaches do not work. This is part of the public company Creative Medical Technology Holdings.


  • Patent 9,205,112 Combination treatment of cardiovascular disease. Covers the augmentation of stem cell activity using intravenous nutrients.  The patent was sold to AngioStem Inc.


  • Patent 9,427,450 Therapeutic immune modulation by stem cell secreted exosomes. Covers the use of nanoparticles called exosomes for modifying the immune system in patients with autoimmune diseases. The patent was sold to Intrexon Inc, a NYSE traded company.


  • Patent 9,433,646 Methods of inhibiting growth of a neoplastic cell. Covers the “teaching” of cancer cells to turn into non-cancerous cells by exposure to placental extracts. The patent was sold to Medistem Inc, which was purchased by Intrexon.


  • Patent 9,682,047 Augmentation of oncology immunotherapies by pterostilbene containing compositions. Covers the use of a blueberry derived extract to increase efficacy of cancer immunotherapies.  The patent was sold to Therapeutic Solutions International, a public company.


  • Patent 8,263,571 Gene silencing of the brother of the regulator of imprinted sites (BORIS). Covers a new way of treating cancer by using gene silencing to block activity of a protein known as the “Achilles Heel” of cancer.

Fibroblast cells.jpg

 Copyright © 2020 FibroGenesis. All rights reserved.